CYCN Stock Analysis: Buy, Sell, or Hold?
CYCN - Cyclerion Therapeutics, Inc. Common Stock
$3.43
0.06 (1.78%)
▲
5d:
+8.2%
30d:
+13.58%
90d:
-46.24%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When CYCN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CYCN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CYCN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CYCN is currently trading at $3.43, which is considered extended relative to its 30-day fair value range of $3.05 to $3.30.
Technical Outlook: Technically, CYCN is in a uptrend. The price is approaching resistance at $3.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CYCN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.00 (+133.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CYCN is in a uptrend. The price is approaching resistance at $3.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CYCN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.00 (+133.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.05 -
$3.30
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 133.2% below Wall St target ($8.00)
Trading Range Analysis
30-Day Trading Range
$3.05 -
$3.30
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.96
Resistance Level
$3.28
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.46
Wall Street Target
$8.00
(+133.2%)
Revenue Growth (YoY)
-43.2%
Profit Margin
-264.7%
Share & Embed Analysis
Last updated: July 02, 2026 10:49 PM ET
Data refreshes hourly during market hours. Next update: 11:49 PM
Data refreshes hourly during market hours. Next update: 11:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CYCN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 64 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
